Background
Acne vulgaris is a common skin problem that may result in significant scarring and systemic co-morbidities. Adverse effects and increasing resistance to available treatments urge the development of new therapeutics. Topical Vitamin D analogs have been successfully used in psoriasis. However, the efficacy and safety of Calcipotriol as a potential topical treatment of Acne is yet to be established.
Objectives
Evaluating the efficacy and safety of Calcipotriol in treating Acne compared to Adapalene and placebo.
Methods
Sixty Acne patients were included and randomly divided into two groups (30 patients each): group I was treated by daily application of Calcipotriol 0.005% cream on one facial side versus placebo (Petrolatum) over the other side. Group II patients were treated by daily applying Adapalene 0.1% gel over one facial side versus Calcipotriol on the other. Therapeutic response was evaluated by the Japanese Acne Grading System (JAGS) and through photographic evaluation using Mean Improvement Score by Physician.
Results
Adapalene treated side showed the best improvement and the highest patient satisfaction compared to those treated with Calcipotriol or placebo (p = 0.001). Nonetheless, the Calcipotriol-treated side showed a significantly greater reduction in post-treatment JAGS and much better satisfaction than the placebo.
As treatment continued, improved tolerability to Calcipotriol was noted, with comparable side effects between the three study arms.
Conclusions
Calcipotriol seems to be a promising new safe topical therapeutic option for Acne. However, Adapalene is still superior in efficacy, tolerability, and patient satisfaction.